- Home
- FBP vs NAMS Comparison
FBP vs NAMS Comparison
Compare FBP & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBP
- NAMS
- Stock Information
- Founded
- FBP 1948
- NAMS 2019
- Country
- FBP United States
- NAMS Netherlands
- Employees
- FBP N/A
- NAMS N/A
- Industry
- FBP Major Banks
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- FBP Finance
- NAMS Health Care
- Exchange
- FBP Nasdaq
- NAMS Nasdaq
- Market Cap
- FBP 3.5B
- NAMS 3.1B
- IPO Year
- FBP N/A
- NAMS N/A
- Fundamental
- Price
- FBP $21.50
- NAMS $32.61
- Analyst Decision
- FBP Buy
- NAMS Strong Buy
- Analyst Count
- FBP 3
- NAMS 9
- Target Price
- FBP $24.00
- NAMS $41.89
- AVG Volume (30 Days)
- FBP 921.1K
- NAMS 974.1K
- Earning Date
- FBP 10-23-2025
- NAMS 11-05-2025
- Dividend Yield
- FBP 3.33%
- NAMS N/A
- EPS Growth
- FBP 2.67
- NAMS N/A
- EPS
- FBP 1.88
- NAMS N/A
- Revenue
- FBP $890,993,000.00
- NAMS $64,006,000.00
- Revenue This Year
- FBP $13.22
- NAMS N/A
- Revenue Next Year
- FBP $5.71
- NAMS $1.67
- P/E Ratio
- FBP $11.50
- NAMS N/A
- Revenue Growth
- FBP 1.81
- NAMS 762.15
- 52 Week Low
- FBP $16.40
- NAMS $14.06
- 52 Week High
- FBP $22.61
- NAMS $34.62
- Technical
- Relative Strength Index (RSI)
- FBP 44.05
- NAMS 73.35
- Support Level
- FBP $21.50
- NAMS $27.15
- Resistance Level
- FBP $22.61
- NAMS $33.27
- Average True Range (ATR)
- FBP 0.45
- NAMS 1.58
- MACD
- FBP -0.09
- NAMS 0.50
- Stochastic Oscillator
- FBP 15.26
- NAMS 79.89
About FBP First BanCorp. New
First BanCorp is a financial holding company. The company's operating segment includes Commercial and Corporate Banking; Mortgage Banking; Consumer (Retail) Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. It generates maximum revenue from the Consumer (Retail) Banking segment. The Consumer (Retail) Banking segment generates majority revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.